cancer cells

A cancer-targeting antibody that helps the body’s immune cells spot and destroy hard-to-treat tumours such as triple-negative breast cancer has been developed by researchers. An electron microscope image showing a tumour cell breaking up and dying (dark red and orange) after being attacked by a natural killer cell on left (red). Image credit: The University

by Steve Martin, Purdue University edited by Andrew Zinin  Editors’ notes  The GIST Add as preferred source Conceptual diagram of the initial electrostatic condensation step for mRNA complexation with CD-PLR10 followed by ELP coating to form LENN via hydrophobic host:guest interactions between the ELP prosthetic groups and the cyclodextrin cavities. Credit: Proceedings of the National Academy of Sciences (2026).

by Kate Rix, Northeastern University edited by Lisa Lock, reviewed by Andrew Zinin  Triple negative breast cancer and melanoma are typically resistant to chemotherapy, says Fleury Augustin Nsole Biteghe. But by attaching a light-sensitive drug to a protein in the cancer cells, and bathing the drug-infused protein in near-infrared light, the cancer cells die. Credit: Matthew Modoono/Northeastern University

A new method can produce custom-designed proteins in just 4-6 weeks that can arm the T cells of the body’s immune system to attack and kill cancer cells Peer-Reviewed Publication Technical University of Denmark image: A new AI-based method can produce specially designed proteins in just a few weeks that can arm the T cells

by Johns Hopkins University School of Medicine edited by Lisa Lock, reviewed by Robert Egan   The discovery shows that the production of ribosomal RNA (rRNA) is connected to how cells manage RNA splicing (a process that edits RNA). In studies of cancer cell lines using drugs that block rRNA production, a new stress response pathway was revealed.